ptk 787 has been researched along with vatalanib in 2 studies
*vatalanib: blocks vascular endothelial growth factor (VEGF) receptor signaling [MeSH]
*vatalanib: blocks vascular endothelial growth factor (VEGF) receptor signaling [MeSH]
| Studies (ptk 787) | Trials (ptk 787) | Recent Studies (post-2010) (ptk 787) | Studies (vatalanib) | Trials (vatalanib) | Recent Studies (post-2010) (vatalanib) |
|---|---|---|---|---|---|
| 5 | 0 | 1 | 276 | 42 | 98 |
| Protein | Taxonomy | ptk 787 (IC50) | vatalanib (IC50) |
|---|---|---|---|
| Bile salt export pump | Homo sapiens (human) | 10 | |
| Epidermal growth factor receptor | Homo sapiens (human) | 0.4577 | |
| Platelet-derived growth factor receptor beta | Homo sapiens (human) | 0.2013 | |
| Mast/stem cell growth factor receptor Kit | Homo sapiens (human) | 0.73 | |
| Vascular endothelial growth factor receptor 1 | Homo sapiens (human) | 0.1192 | |
| Vascular endothelial growth factor receptor 3 | Homo sapiens (human) | 0.1475 | |
| Vascular endothelial growth factor receptor 2 | Homo sapiens (human) | 0.378 | |
| Vascular endothelial growth factor receptor 2 | Danio rerio (zebrafish) | 0.49 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Acemoglu, F; Altmann, KH; Bold, G; Boss, E; Brüggen, J; Buchdunger, E; Cozens, R; Emmenegger, R; Ferrari, S; Frei, J; Furet, P; Hofmann, F; Lang, M; Lässer, L; Manley, PW; Martiny-Baron, G; Masso, E; Mestan, J; Rösel, J; Roth, R; Schlachter, C; Sills, M; Stover, D; Traxler, P; Vetterli, W; Wietfeld, B | 1 |
| Bold, G; Brüggen, J; Furet, P; Haberey, M; Huth, A; Krüger, M; Manley, PW; Menrad, A; Mestan, J; Meyer, T; Ottow, E; Schnell, CR; Seidelmann, D; Siemeister, G; Thierauch, KH; Wood, J | 1 |
2 other study(ies) available for ptk 787 and vatalanib
| Article | Year |
|---|---|
New anilinophthalazines as potent and orally well absorbed inhibitors of the VEGF receptor tyrosine kinases useful as antagonists of tumor-driven angiogenesis.
Topics: Administration, Oral; Angiogenesis Inhibitors; Aniline Compounds; Animals; Biological Availability; Cell Line; CHO Cells; Cricetinae; Enzyme Inhibitors; Humans; Mice; Models, Molecular; Neoplasms; Neovascularization, Pathologic; Phosphorylation; Phthalazines; Proto-Oncogene Proteins; Pyridines; Receptor Protein-Tyrosine Kinases; Receptors, Growth Factor; Receptors, Vascular Endothelial Growth Factor; Structure-Activity Relationship; Transfection; Vascular Endothelial Growth Factor Receptor-1 | 2000 |
Anthranilic acid amides: a novel class of antiangiogenic VEGF receptor kinase inhibitors.
Topics: Administration, Oral; Amides; Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Benzamides; CHO Cells; Cricetinae; Enzyme Inhibitors; Female; Humans; Isoquinolines; Lymphatic Metastasis; Melanoma; Mice; ortho-Aminobenzoates; Phosphorylation; Receptors, Vascular Endothelial Growth Factor | 2002 |